Impact on Patients’ Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial
Open Access
- 27 April 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (4), e0123252
- https://doi.org/10.1371/journal.pone.0123252
Abstract
The impact on treatment outcomes of XpertMTB/RIF, a molecular-based test that provides rapid diagnosis of tuberculosis (TB) and rifampicin resistance with high accuracy, has not been reported despite its adoption in a few countries. We here report treatment outcomes in a step-wedged cluster randomized trial for patients diagnosed with XpertMTB/RIF compared to patients diagnosed with sputum smear examination in public health facilities in Brazil. Treatment outcome data were added to the trial database of patients diagnosed from 4 February to 4 October 2012, and crosschecked with data from the national mortality and the drug-resistant TB registers. Treatment outcomes in the intervention (n=2232) and baseline (n=1856) arms were compared using a multilevel regression model. Unfavourable outcomes were frequent in both arms, mainly due to loss to follow-up (16%). Overall unfavourable outcomes were not reduced in the intervention arm (29.6% versus 31.7%, OR=0.93; 95%CI=0.79-1.08). However, the overall TB-attributed death rate was lower in the intervention arm (2.3% vs. 3.8%). Adjusted for HIV status, age group and city, the intervention resulted in a 35% decrease in TB-attributed deaths (OR=0.65, 95%CI=0.44-0.97). The proportion of patients successfully treated did not increase with Xpert MTB/RIF implementation, with high loss to follow-up rates in both arms. We did observe a 35% reduction in TB-related mortality, which we hypothesize may be explained by less advanced disease among the smear-negative patients diagnosed by Xpert. In conclusion, XpertMTB/RIF introduction did not improve TB treatment outcomes in Brazil. clinicaltrials.gov NCT01363765Keywords
This publication has 13 references indexed in Scilit:
- Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?The Lancet Infectious Diseases, 2014
- Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trialThe Lancet, 2014
- GeneXpert MTB/RIF Version G4 for Identification of Rifampin-Resistant Tuberculosis in a Programmatic SettingJournal of Clinical Microbiology, 2014
- Xpert (R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsEmergencias, 2013
- Clinical Predictors and Accuracy of Empiric Tuberculosis Treatment among Sputum Smear-Negative HIV-Infected Adult TB Suspects in UgandaPLOS ONE, 2013
- Xpert (R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review)Published by Wiley ,2012
- Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic ReviewPLOS ONE, 2011
- Rapid Molecular Detection of Tuberculosis and Rifampin ResistanceThe New England Journal of Medicine, 2010
- Reducing the global burden of tuberculosis: the contribution of improved diagnosticsNature, 2006
- Reclink: aplicativo para o relacionamento de bases de dados, implementando o método probabilistic record linkageCadernos de Saude Publica, 2000